Question:

Don't attempt if you are not sure

In this problem the geometric(p) distribution is defined as the total number of trials to the first failure (the value includes the failure), where p is the probabilitiy of success.

(a) What sample statistic would you use to estimate p?

(b) Describe how you would use the parametric bootstrap to estimate a 95% confidence

interval for p. You can be brief, but you should give careful step-by-step instructions.

Briefs ofamici curiaeurging affirmance were filed byLawrence A. PoltrockandWayne B. Giampietrofor the American Federation of Teachers; byAbraham S. Goldstein, Nathan Z. Dershowitz, Arthur J. Gajarsa, Thaddeus L. Kowalski, Anthony J. Fornelli, Howard L. Greenberger, Samuel Rabinove, Themis N. Anastos, Julian E. Kulas,andAlan M. Dershowitzfor the American Jewish Committee et al.; byMcNeill StokesandIra J. Smotherman, Jr.,for the American Subcontractors Assn.; byPhilip B. Kurland, Daniel D. Polsby, Larry M. Lavinsky, Arnold Forster, Dennis Rapps, Anthony J. Fornelli, Leonard Greenwald,andDavid I. Ashefor the Anti-Defamation League of B'nai B'rith et al.; byCharles G. BakalyandLawrence B. Krausfor the Chamber of Commerce of the United States; byRoger A. Clark, Jerome K. Tankel,andGlen R. Murphyfor the Fraternal Order of Police et al.; byJudith R. Cohnfor the Order Sons of Italy in America; byRonald A. Zumbrun, John H. Findley,andWilliam F. Harveyfor the Pacific Legal Foundation; byBenjamin VinarandDavid I. Caplanfor the Queens Jewish Community Council et al.; and byJennings P. Felixfor Young Americans for Freedom.

Question 11

I am a third-year student nurse and am currently researching a case study based on the biopsychosocial history of a patient who suffers from chronic hepatitis C, which initially occurred as a result of injecting drugs. I am confused about the biological effect of hepatitis: how exactly does it affect the liver?

Question 12

What are the admission criteria for a case of acute viral hepatitis?

Question 13

I would like to know where I can find details on hepatitis B virus (HBV) infection: chronic carrier, asymptomatic [normal liver function tests, HBV DNA/real-time polymerase chain reaction (PCR)240 copies/mL, core less than 0.1]. Does a patient with such a profile need therapy or fine needle aspiration (FNA) biopsy? What is the possibility of hepatocellular carcinoma (HCC) in such a patient?

Question 14

In chronic hepatitis B virus (HBV) infection, when anti-hepatitis B e antibody (anti-HBe) develops (seroconversion), the antigen disappears and there is a rise in alanine transferase (ALT). However, the graph in your book (K&C 7e, p. 337, Fig. 7.16) seems to show a fall in ALT at this point. Which is correct?

Question 15

Interferon can be used in prophylaxis from hepatitis C after exposure. Could you explain how this can be used, and what degree of success can be expected as a result?

Question 16

What is the latest recommended drug treatment for hepatitis C?

Question 17

Can hepatitis C disease be treated in a carrier state completely by giving

interferon?

Question 18

I am a carrier of hepatitis C (HCV) and am going to have antiviral treatment soon. Are the side-effects of antiviral treatment for HCV bound to occur? I am very worried.

Question 19

Besides needle-pricks, how else is it possible to contract hepatitis C from a hepatitis C (HCV)-positive patient? Are the patient's skin/sweat (or other bodily secretions) infectious?

Question 20

What is the risk of infection with hepatitis C from blood splashed into the eyes?